Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 31c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.25), $0.31 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $126.17 million versus the consensus estimate of $119.72 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
• Activist Corvex seeks Whitbread board seat over strategy concerns